By: Brielle Benyon
Advanced practice providers discuss the second-line use of elacestrant in patients with co-mutated, ER+, HER2—advanced or metastatic breast cancer
Brielle Benyon is an Assistant Managing Editor at CURE Media Group, OncLive, and Oncology Nursing News. With a focus on oncology and healthcare, Brielle's articles cover a wide range of topics including patient experiences, medical advancements, clinical trials, and the impact of cancer on various aspects of life. She is dedicated to providing informative and supportive content to those affected by cancer.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Brielle Benyon's coverage focuses heavily on healthcare and pharmaceutical topics, particularly in the field of oncology. The articles she covers often include data citations and expert commentary, indicating a strong emphasis on evidence-based reporting.
Given this focus, Brielle would likely be responsive to pitches from experts in the fields of oncology, cancer treatment, clinical trials, breast cancer research, and MPNs (Myeloproliferative Neoplasms). Sources with access to recent data or those who can provide insightful commentary based on evidence are also likely to resonate well with her.
As there is no specified geographic focus for Brielle's coverage area, relevant information or expertise from any location could be suitable for pitching.
This information evolves through artificial intelligence and human feedback. Improve this profile .